NASDAQ: DAWN
Day One Biopharmaceuticals is a pioneering company focused on creating targeted therapies for individuals with genetically specific cancers. At the forefront of their innovative pipeline is tovorafenib, a promising treatment designed to penetrate the brain and combat pediatric low-grade glioma in its advanced trial stages. Additionally, they are developing Pimasertib, aimed at inhibiting key cancer growth pathways. Founded in 2018 and based in Brisbane, California, Day One is committed to transforming cancer treatment for patients with critical needs.
Pre-Market Stock Futures: Futures are trading lower as we hit the mid-point of the trading week, and while we didn’t see the snapback rally that was the star of the show Monday,…
Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday.…
Day One Biopharmaceuticals is a pioneering company focused on creating targeted therapies for individuals with genetically specific cancers.
